Investor's Business Daily on MSN
Why Arrowhead shot sky-high, while chief rival Ionis toppled
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to ...
Arrowhead Pharmaceuticals (ARWR) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in ...
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are ...
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pfizer (PFE) stock, Alnylam (ALNY) stock and BridgeBio (BBIO) stock jump after a trial setback for an ATTE-CM drug from Astra ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
Biogen (BIIB) stock dips as the company updates Phase 2 trial data for diranersen, an Alzheimer’s drug developed with Ionis ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living ...
Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results